10 completed, 5 terminated, 2 recruiting, 1 active not recruiting. 19 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 10, Terminated 5, Recruiting 2, Active not recruiting 1, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Hyperkalemia: new trials by email Literature Review of Hyperkalemia trials Research Report on Hyperkalemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Urea to the Final Dialysis Fluid Urea in the dialysate - Dysequilibrium Syndrome, ESRD | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 20 | 2025-09-16 | 2026-02-12 |
| Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels Patiromer - Hyperkalemia | Phase 2 | Recruiting | Vifor Pharma, Inc. | 36 | 2025-04-06 | 2026-09-25 |
| A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia. WS016 3g, WS016 6g, WS016 12g - Hyperkalemia | Phase 2 | Unknown | Waterstone Pharmaceutical (Wuhan) Co., LTD. | 140 | 2023-09-11 | 2024-02-26 |
| The ORTIZ Study: Optimising RASi Therapy With SZC Sodium Zirconium Cyclosilicate, Placebo - CKD, Diabetes Mellitus, Type 2 | Phase 2 | Terminated | Barts & The London NHS Trust | 18 | 2022-06-17 | 2025-06-08 |
| OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure Sodium zirconium cyclosilicate, Placebo - Heart Failure, Hyperkalemia | Phase 2 | Active not recruiting | Michael Fu | 110 | 2021-09-01 | 2025-07-04 |
| A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia RDX013, Placebo - Hyperkalemia | Phase 2 | Completed | Ardelyx | 109 | 2021-01-11 | 2022-05-04 |
| Exploratory Study of ZG-801 for the Treatment of Hyperkalemia patiromer, placebo - Hyperkalemia | Phase 2 | Completed | Zeria Pharmaceutical | 184 | 2019-02-18 | 2021-03-25 |
| Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure Sodium Zirconium Cyclosilicate, Placebo - Heart Failure | Phase 2 | Terminated | AstraZeneca | 182 | 2018-06-26 | 2021-06-15 |
| A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8 Placebo, Sodium Zirconium Cyclosilicate(ZS), Insulin - Hyperkalemia | Phase 2 | Completed | AstraZeneca | 70 | 2018-02-13 | 2020-01-28 |
| The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia Patiromer - ESRD, Hyperkalemia | Phase 2 | Completed | Dominic Raj | 27 | 2017-11-01 | 2023-05-09 |
| Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia Patiromer - Hyperkalemia | Phase 2 | Terminated | Vifor Pharma, Inc. | 23 | 2017-07-07 | 2022-10-19 |
| ZS Ph2/3 Dose-response Study in Japan Sodium Zirconium Cyclosilicate (ZS) 5g, Sodium Zirconium Cyclosilicate (ZS) 10g, Placebo - Hyperkalemia | Phase 2 / Phase 3 | Completed | AstraZeneca | 103 | 2017-06-14 | 2019-05-20 |
| Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease Patiromer, Placebo, Spironolactone - Hyperkalemia, Resistant Hypertension | Phase 2 | Completed | Relypsa, Inc. | 295 | 2017-01-23 | 2021-05-12 |
| A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia RDX227675, Placebo - Hyperkalemia | Phase 2 | Terminated | Ardelyx | 60 | 2017-01-01 | 2019-12-26 |
| Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia Zirconium silicate (ZS), Placebo - Hyperkalemia, Chronic Kidney Disease | Phase 2 | Completed | ZS Pharma, Inc. | 90 | 2011-11-30 | 2018-06-29 |
| Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN) patiromer, losartan, spironolactone - Chronic Kidney Disease, Hypertension | Phase 2 | Completed | Relypsa, Inc. | 324 | 2011-06-01 | 2021-06-03 |
| Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease patiromer, spironolactone - Heart Failure | Phase 2 | Completed | Relypsa, Inc. | 63 | 2010-05-01 | 2021-05-12 |
| Evaluation of Patiromer in Heart Failure Patients patiromer, placebo - Hyperkalemia, Heart Failure | Phase 2 | Completed | Relypsa, Inc. | 120 | 2009-04-01 | 2021-06-02 |
| An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis patiromer - Hyperkalemia | Phase 2 | Terminated | Relypsa, Inc. | 6 | 2008-08-01 | 2021-05-12 |
Renal Insufficiency, Chronic (6) · Heart Failure (4) · Hypertension (2) · Kidney Failure, Chronic (2) · Acidosis (1) · Diabetes Mellitus, Type 2 (1) · Diabetic Nephropathies (1) · Dysequilibrium syndrome (1)
Metabolic Diseases (19) · Nutritional and Metabolic Diseases (19) · Water-Electrolyte Imbalance (19) · Chronic Disease (8) · Disease Attributes (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Kidney Diseases (8) · Male Urogenital Diseases (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Renal Insufficiency (8) · Urogenital Diseases (8) · Urologic Diseases (8) · Cardiovascular Diseases (6)
patiromer (9) · sodium zirconium cyclosilicate (5) · Suspensions (4) · Spironolactone (3) · Glucose (1) · Insulin (1) · Losartan (1) · Urea (1) · zircon (1)
Relypsa, Inc. (5) · AstraZeneca (3) · Ardelyx (2) · Vifor Pharma, Inc. (2) · Barts & The London NHS Trust (1) · Dominic Raj (1) · Michael Fu (1) · University of California, San Francisco (1) · Waterstone Pharmaceutical (Wuhan) Co., LTD. (1) · ZS Pharma, Inc. (1) · Zeria Pharmaceutical (1)
United States (12) · Georgia (5) · Poland (4) · Bulgaria (3) · Germany (3) · Hungary (3) · Russia (3) · Ukraine (3) · Canada (2) · Croatia (2) · Italy (2) · Japan (2) · Romania (2) · Slovenia (2) · United Kingdom (2)
Julian Platon, MD, PhD (2) · David P Rosenbaum, Ph.D. (1) · Frank Peacock, MD (1) · Henrik Rasmussen, MD (1) · Jean-Claude Tardif (1) · Keiran McCafferty (1) · Michael Fu, Professor (1) · Ramin Sam, MD (1)
PMID 32588430, PMID 21208974, PMID 29369537, PMID 29767459, PMID 30176673, PMID 31533906, PMID 32149451, PMID 32750456, PMID 32779057, PMID 34136782, PMID 35369022, PMID 36564955
2016 (2), 2017 (1), 2023 (1)